Skin Cancer Diagnostics

Global Skin Cancer Diagnostics Market to Reach US$11.7 Billion by 2030

The global market for Skin Cancer Diagnostics estimated at US$9.4 Billion in the year 2024, is expected to reach US$11.7 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. Melanoma, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Non-Melanoma segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.5 Billion While China is Forecast to Grow at 6.8% CAGR

The Skin Cancer Diagnostics market in the U.S. is estimated at US$2.5 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 6.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.6% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Skin Cancer Diagnostics Market – Key Trends & Drivers Summarized

Why Is Skin Cancer Diagnostics Becoming a Global Healthcare Priority? Examining the Rising Incidence of Skin Malignancies

The growing prevalence of skin cancer, particularly melanoma and non-melanoma variants such as basal cell carcinoma and squamous cell carcinoma, has made early detection a critical priority in dermatology and oncology. Factors such as increased UV exposure, climate change, genetic predisposition, and lifestyle habits have contributed to the rising incidence of skin malignancies worldwide. With public health initiatives emphasizing the importance of early diagnosis, advancements in skin cancer diagnostics have played a crucial role in improving survival rates. Traditional diagnostic methods such as visual inspection and biopsy remain the gold standard, but the introduction of non-invasive imaging technologies has transformed the diagnostic landscape. Additionally, increasing awareness campaigns and routine skin checks have encouraged more individuals to seek early screening, leading to higher detection rates. As healthcare systems continue to focus on preventive care, the demand for accurate and efficient skin cancer diagnostic tools is expected to rise significantly.

How Are Technological Innovations Enhancing Skin Cancer Diagnostics? Exploring the Role of AI, Imaging, and Molecular Testing

The field of skin cancer diagnostics has witnessed significant advancements, with cutting-edge technologies improving detection accuracy and reducing the need for unnecessary biopsies. Dermoscopy, confocal laser scanning microscopy, and reflectance confocal microscopy have provided dermatologists with high-resolution imaging capabilities, allowing for real-time evaluation of suspicious lesions. Artificial intelligence (AI) and machine learning have further revolutionized the field, with AI-powered algorithms capable of analyzing skin images and identifying cancerous patterns with remarkable precision. Additionally, genetic and molecular diagnostics have emerged as powerful tools in skin cancer detection, enabling the identification of genetic mutations associated with melanoma risk. Liquid biopsy techniques are also being explored for their potential to detect circulating tumor DNA (ctDNA) in blood samples, providing a minimally invasive alternative to traditional biopsy methods. As these innovations continue to evolve, skin cancer diagnostics are becoming more accessible, efficient, and reliable.

What Challenges Are Hindering the Adoption of Advanced Skin Cancer Diagnostic Tools? Addressing Cost, Accessibility, and Regulatory Issues

Despite the technological progress in skin cancer diagnostics, several challenges remain, including cost barriers, accessibility issues, and regulatory complexities. Advanced imaging systems and AI-driven diagnostic platforms require significant investment, making them less accessible in low-income and remote areas where skin cancer detection is needed most. Additionally, variations in healthcare infrastructure across regions impact the availability of skilled dermatologists and oncologists who can interpret diagnostic results accurately. The integration of AI into dermatology also raises regulatory concerns, as ensuring the reliability and standardization of AI-based diagnostic tools remains a key hurdle. Furthermore, patient awareness about early screening and the benefits of non-invasive diagnostics is still limited in many parts of the world, leading to delayed diagnoses and poorer outcomes. Overcoming these challenges requires strategic efforts in cost reduction, regulatory alignment, and broader implementation of telemedicine solutions to improve global skin cancer detection rates.

What’s Driving the Growth of the Skin Cancer Diagnostics Market? Identifying Key Expansion Factors and Industry Trends

The growth in the skin cancer diagnostics market is driven by several factors, including increasing incidence rates of skin cancer, advancements in diagnostic technology, and the rising adoption of AI-powered screening solutions. The growing burden of melanoma and non-melanoma skin cancers has led governments and healthcare organizations to invest in early detection programs, further boosting demand for diagnostic tools. The rise of teledermatology and AI-based image analysis has expanded access to skin cancer screening, allowing for remote assessments and faster diagnosis. Additionally, increasing consumer awareness about the dangers of UV exposure and the importance of routine skin checks has encouraged proactive health monitoring. Innovations in genetic and molecular testing have also opened new avenues for precision diagnostics, enabling more targeted and effective treatment strategies. With continuous improvements in diagnostic accuracy, affordability, and accessibility, the skin cancer diagnostics market is expected to experience significant expansion, shaping the future of dermatological oncology.

SCOPE OF STUDY:

The report analyzes the Skin Cancer Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Cancer Type (Melanoma, Non-Melanoma); Test Type (Dermatoscopy, Skin Biopsy, Lymph Node Biopsy, Imaging Tests, Others); End-Use (Hospitals & Clinics, Laboratories, Others)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Abbott Laboratories
• Amgen Inc.
• AMLo Biosciences
• Bristol-Myers Squibb Company
• Caliber Imaging & Diagnostics, Inc.
• Canfield Scientific, Inc.
• Castle Biosciences, Inc.
• Daiichi Sankyo Company, Limited
• DermaSensor, Inc.
• DermLite
• DermTech
• F. Hoffmann-La Roche Ltd
• FotoFinder Systems GmbH
• Genomic Health (Exact Sciences)
• Laboratory Corporation of America
• Merck & Co., Inc.
• Michelson Diagnostics
• Myriad Genetics
• Neko Health
• NeoGenomics Laboratories
• Novartis AG
• Pfizer Inc.
• Proscia
• QIAGEN
• Sanofi
• Scailyte AG
• Sirnaomics, Inc.
• SkinVision
• Sun Pharmaceutical Industries Ltd
• Veriskin Inc

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.